Followers | 38 |
Posts | 4010 |
Boards Moderated | 0 |
Alias Born | 11/09/2016 |
Saturday, March 17, 2018 9:58:21 PM
We have platforms for extracting neurotoxins from cobra venom and making them nontoxic and therapeutic. We can synthesize the peptides or make them through fermentation. The platform is unique.
That's the core of our intellectual property. We have 21 patents, but three are key: one for autoimmune disease, one for pain, and one for antiviral therapeutics. These patents protect different ways of modifying biologics, or modifying native cobra venom.
Normally, there is one drug for any given autoimmune disease. In contrast, we have a drug that modulates the body's immune response. Theoretically, therefore, the drug could work in any autoimmune disease. We've been working principally in MS, but we've also looked at myasthenia gravis, rheumatoid arthritis, Hashimoto's thyroiditis and type 1 diabetes. We believe we can prove our drug would be incredibly effective in all these diseases.
The prescription drugs we're working on also generate great benefits without the side effects usually associated with autoimmune and viral disease treatments. Additionally, because we modify these peptides and clinically denature them, they're shelf-stable. They don't require any special handling or expensive refrigeration, which normally is needed for peptide products or biologics. Therefore, it becomes much more cost-effective to produce our medications and to treat patients.
Our antiviral drug is a fusion inhibitor, like a couple of drugs already on the market. The problem with the existing drugs, however, is that they only block one receptor, allowing viruses to mutate around them. They also tend to be very expensive and difficult to manufacture. RPI-MN, in contrast, is very inexpensive and easy to make. In fact, with our drug, we could treat viral disorders—even HIV—for $1 per day and still make money.
FEATURED Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • May 17, 2024 11:00 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM